General Proximity (YC W20) — The next generation of induced-proximity medicines
General Proximity appears in Y Combinator's company directory in the Winter 2020 batch, listed 2024-12-18. The next generation of induced-proximity medicines..
General Proximity is a Y Combinator company in the Winter 2020 batch. Its directory entry describes it as: The next generation of induced-proximity medicines. The founder listed is Armand Cognetta (Founder) (Y Combinator directory entry, December 18, 2024).
Get an email when General Proximity changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
General Proximity pioneers next-generation medicines by controlling biological processes through proximity. Redefining the future of medicine for all humankind.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Armand Cognetta
Founder
Armand completed his PhD in Chemical Biology at the Scripps Research Institute under the supervision of Dr. Benjamin F. Cravatt. There he co-authored 19 scientific publications in prestigious journals such as Cell, Nature, and Science, as well as multiple patents, including a portion of the foundational IP for Abide Therapeutics (acq. Lundbeck) and Vividion Therapeutics (acq. Bayer). Prior to founding GP he was an early employee at the Flagship Pioneering start-up Inzen Tx (now Sonata).
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
One of 60 companies held here in Healthcare › Drug Discovery and Delivery.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Want the whole picture on General Proximity?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on General Proximity: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on General Proximity covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind General Proximity: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
General Proximity (YC W20) — The next generation of induced-proximity medicines. MentionFox, 2026-10-20. https://mentionfox.com/funding/yc-general-proximity
